Explore the Agenda
7:30 am Check In & Refreshments
8:20 am Chair’s Opening Remarks
Defining the Future of Induced Proximity & Translating Scientific Innovation Into Clinically Transformative Therapies for Patients with Unmet Medical Need
8:30 am Degradation Delivered – What the First TPD Approval Means for the Future of the Field
- Significance of the first approved targeted protein degrader
- What the future of TPD holds beyond oncology; other targets to explore and consider
- High-level overview of what is next for Arvinas, it’s pipeline and targets
9:00 am Panel Discussion: Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact
- Examining recent advances across degrader and non-degrader modalities, highlighting how new discoveries are moving the field beyond oncology
- Assessing the influence of global markets, including China, on drug development, the clinical landscape and strategic collaborations in induced proximity therapeutics
- Identifying emerging opportunities, bottlenecks, and the next frontiers in translating platform innovations into clinically relevant therapies
9:30 am Probing Degrader Safety Liabilities and Target Biology in Relevant Cellular Contexts
- Flagging CRBN neosubstrate liabilities with a Lumit immunoassay panel for rapid degradation profiling in unmodified cells
- Uncovering cell context-dependent degradation potency, highlighting the importance of disease-relevant models for translational research
- Developing next-generation tagging tools to study endogenous target biology and degradation
10:00 am Inducing the Selective Degradation of Cyclin D1 by Interfering with its Folding Pathway
- Application of physics-based computational simulations to map the folding landscape of Cyclin D1 and identify ligandable pockets exposed along its folding pathway
- Discovery and optimization of small molecules that engage a folding intermediate of Cyclin D1, perturb its folding pathway, and induce selective degradation of the nascent protein
- In vitro and in vivo evidence supporting pharmacological targeting of the Cyclin D1 folding pathway as a novel therapeutic strategy
10:30 am Morning Break & Speed Networking
This is your opportunity to connect with your TPD & Induced Proximity peers to exchange business cards, discuss your research and forge the future of drug development
Track A: Discovery
Expanding the Ligase Toolbox & Pursuing Novel Ligases to Overcome the Limitations of Cereblon & Expand Therapeutic Scope
Chief Executive Officer & Founder, Concarlo Holdings LLC
11:30 am Expanding the Degrader Toolbox for Neuro Applications
Chief Executive Officer, Trimtech Therapeutics
- Differentiation of TRIMTECH’s TRIM21 platform and applicability to neurodegeneration
- Data supporting selective and potent degradation of toxic protein aggregates
- Bifunctional and molecular glue strategies for these target classes
12:00 pm A Proteome-Wide Screening Engine Delivering Partner-Ready Molecular Glue Degraders at Scale
Chief Scientific Officer, NEOsphere Biotechnologies GmbH
- Large-scale proteomic library screening has identified molecular glue degraders against 300+ targets — including CDK4 — across indications from I&I to oncology, ready to license and fuel partner programs
- Linking chemical structures of entire libraries to proteome-wide degradation and interactome profiles supports selectivity optimization and SAR
- Proteomics-driven AI/ML enables rational molecular glue prediction and design — shortening discovery timelines and increasing hit-to-lead success rates
12:30 pm A Novel TPD Platform Leveraging a New E3 Ligase to Minimize Hematologic Toxicity
Founder & Chief Executive Officer, Pin Therapeutics
- Introduction of a novel TPD platform with a differentiated profile based on a new E3 ligase
- Data highlighting efficient target degradation with reduced hematologic off-target effects
- Insights into strategies to mitigate toxicity risk in future TPD development
1:00 pm Lunch Break & Networking Time
Building Integrated Discovery Platforms to Enable Induced Proximity Innovation through Advanced Chemistry, Assays & Screening Technologies
2:00 pm MOPED™ Molecular Proximity Enabled Detection : A Novel Platform for the Discovery of Molecular Glue
Senior Director - Biochemistry & Biophysics, SK Life Science Labs
- MOPED is a high-throughput, multiplexed screening platform capable of identifying weak molecular glues
- It can identify compounds that induce a productive POI-E3 ternary complex
- The platform is adaptable for applications beyond TPD
2:30 pm Accelerating Protein Degrader Therapeutics Through Integrated Discovery Solutions
Senior Director, Business Development & Marketing, SAI Life Sciences Ltd
- Targeted protein degradation is transforming drug discovery beyond conventional target inhibition
- Success in the TPD field requires integration of biology, chemistry, DMPK, structural biology, and translational sciences
- End-to-end discovery platform at Sai Life Sciences can significantly accelerate degrader advancement from concept to candidate
2:40 pm Mechanism-Agnostic Molecular Glue Discovery in Living Cells
Co-Founder & Chief Scientific Officer, Serinus Biosciences
- ApoXY tests hundreds of protein pairs in living cells at once — capturing degradation, stabilization, shielding, rewiring, and more in a single screen.
- Systematic mapping of chemically inducible biology surfaces glue opportunities invisible to degradation-based methods.
- First-in-class glues advancing in oncology and immunology.
3:10 pm Decoding RIPTAC Mechanism of Action: Deep Data Mining & Target-Effector Pair Differentiation in Novel Proximity-Based Therapeutics
Senior Vice President, Head of Biology, ICE Bioscience
- AI & mechanistic biology dissection of RIPTAC MoA: AI modeling and proprietary biological modules to characterize AR-BRD4 / ER-BRD4 target-effector pairs
- Core strengths of RIPTAC: Mechanistic superiority, better safety and wider therapeutic index versus traditional small-molecule inhibitors
- Novel pair of EP and TP validation: Multi-layer biophysical/cellular assays plus computational modeling to validate targets and derisk early drug discovery pipelines
3:40 pm Afternoon Break & Poster Session
Building Integrated Discovery Platforms to Enable Induced Proximity Innovation through Advanced Chemistry, Assays & Screening Technologies
4:30 pm How NanoTemper Solutions Assist Degrader Workflows, from Initial Screening, Over Optimization to In-Depth Characterization
Product Manager, NanoTemper Technologies
- Identifying novel Cereblon binders from a high-diversity library using high-throughput screening on Dianthus uHTS
- Investigating the intrinsic cooperativity of a ternary system facilitated by macrocyclic molecular glues using Dianthus α
- Presenting the comprehensive biophysical characterization of the VCB–MZ1–BRD2 complex using Monolith Omni to demonstrate how high throughput screening, affinity measurements, and quantitative ternary-complex analysis can help guide the discovery and optimization of degraders and molecular glues
5:00 pm Harnessing Sphingolipid Biology for Targeted Degradation of Soluble & Membrane Proteins
Co-Founder & Chief Scientific Officer, Transcera Inc.
- Building on fundamental discoveries in sphingolipid biology, Transcera develop a new modality for extracellular protein degradation that harness native ceramide trafficking pathways
- Transcera’s degraders work across multiple cell types in tissues throughout the body and have extended half-life for durable target depletion,
- Transcera discovered new degraders for immune-mediated disease and is advancing towards a clinical candidate
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development